Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Collegium Pharmaceutical Inc. COLL

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. It is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza...


Recent & Breaking News (NDAQ:COLL)

Collegium Provides 2023 Financial Guidance

GlobeNewswire January 4, 2023

Appeals Court Affirms Validity of Collegium's Belbuca® Patents

GlobeNewswire December 22, 2022

Collegium to Participate in Piper Sandler 34th Annual Healthcare Conference

GlobeNewswire November 22, 2022

Collegium Reports Third Quarter 2022 Financial Results

GlobeNewswire November 3, 2022

Collegium to Report Third Quarter 2022 Financial Results on November 3, 2022

GlobeNewswire October 20, 2022

Collegium Announces 11 Poster Presentations at PAINWeek 2022 National Conference

GlobeNewswire August 30, 2022

Collegium Reports Second Quarter 2022 Financial Results

GlobeNewswire August 4, 2022

Collegium to Report Second Quarter 2022 Financial Results on August 4, 2022

GlobeNewswire July 21, 2022

Collegium to Participate in H.C. Wainwright Global Investment Conference

GlobeNewswire May 17, 2022

Collegium Reports First Quarter 2022 Financial Results

GlobeNewswire May 10, 2022

Collegium to Host Conference Call to Discuss First Quarter 2022 Financial Results

GlobeNewswire April 26, 2022

Collegium to Participate in Upcoming Needham Healthcare Conference

GlobeNewswire April 7, 2022

Collegium Appoints Neil McFarlane to its Board of Directors

GlobeNewswire April 6, 2022

Collegium Provides 2022 Financial Guidance

GlobeNewswire April 5, 2022

Collegium Announces Master Settlement Agreement Resolving Pending Opioid-Related Litigation

GlobeNewswire March 30, 2022

Collegium Completes the Acquisition of BDSI

GlobeNewswire March 22, 2022

Collegium Reports Fourth Quarter and Full-Year 2021 Financial Results

GlobeNewswire February 24, 2022

BIODELIVERY SCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioDelivery Sciences International, Inc. - BDSI

PR Newswire February 16, 2022

SHAREHOLDER ALERT: WeissLaw LLP Investigates BioDelivery Sciences International, Inc.

PR Newswire February 15, 2022

Collegium to Acquire BioDelivery Sciences in an All-Cash Deal

GlobeNewswire February 14, 2022